BevCanna Enterprises

COMPASS PATHWAYS NASDAQCMPS STOCK QUOTE

https://compasspathways.com/

LATEST NEWS FROM COMPASS PATHWAYS

COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs

Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds

COMPASS Pathways to participate in Citi, Morgan Stanley and HC Wainwright investor conferences in September

COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021

COMPASS Pathways plc to announce second quarter 2021 financial results on 11 August 2021

COMPASS Pathways to Participate in BTIG and Canaccord Genuity Investor Conferences

Guy Goodwin joins COMPASS Pathways as Chief Medical Officer

Danielle Schlosser joins COMPASS Pathways from Verily Life Sciences to lead clinical innovation and therapist training

COMPASS Pathways to participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit

COMPASS Pathways joins forces with King’s College London and South London and Maudsley NHS Foundation Trust to accelerate psychedelic research and develop new models of mental health care in the UK

COMPASS Pathways launches new podcast “Everyone has a story: talking about mental health”

COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depression

COMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural Scholars programme

COMPASS Pathways plc to participate in JMP Securities and H.C. Wainwright investor conferences

COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers

COMPASS Pathways plc announces financial results and business highlights for the first quarter 2021

COMPASS Pathways plc to announce first quarter 2021 financial results on 13 May 2021

COMPASS Pathways announces pricing of public offering

COMPASS Pathways launches proposed public offering

New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder

COMPASS Pathways plc to participate in 20th Annual Needham Virtual Healthcare Conference

COMPASS Pathways appoints Wayne J Riley MD to its Board of Directors

COMPASS Pathways granted two US patents

COMPASS Pathways plc announces financial results and business highlights for fourth quarter and year-end 2020

COMPASS Pathways plc to announce fourth quarter and full year 2020 financial results on 9 March 2021

COMPASS Pathways plc to participate in Cowen's 41st Annual Health Care Conference